GlassScriptPhysician profile
Patrick D Hawkins
NPI 1902803877
$4,729.36
in general payments reported to CMS, 2019-2025
26 companies · $1,598 in 2025
The $1,598 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $733 · 2022: $399 · 2023: $991 · 2024: $1,008 · 2025: $1,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568 · Education: $29.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,567.89 |
| Education | $29.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.39 | 2022-2025 | |
| Alkermes, INC. | $723.47 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $470.30 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $355.51 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $346.08 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $302.47 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $288.87 | 2021-2025 | Caplyta |
| Akebia Therapeutics INC | $242.46 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $166.17 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $115.42 | 2023 | Quviviq |
| Vifor Pharma, INC. | $111.94 | 2021-2022 | |
| Braeburn INC. | $81.30 | 2024 | Brixadi |
| Coloplast Corp | $70.77 | 2025 | |
| Janssen Pharmaceuticals, INC | $66.46 | 2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $45.07 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $41.51 | 2021 | |
| Amgen INC. | $35.64 | 2021-2022 | |
| Glaxosmithkline, LLC. | $33.26 | 2021 | |
| Fresenius USA Marketing, INC. | $32.55 | 2021 | |
| Vanda Pharmaceuticals INC. | $30.97 | 2025 | Fanapt |
| Novo Nordisk INC | $28.93 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $28.65 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $22.12 | 2021 | |
| Astellas Pharma US INC | $20.95 | 2024 | Veozah |
| Ultragenyx Pharmaceutical INC. | $18.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hawkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.